These divergent trajectories mandate histology-specific management algorithms rather than uniform colorectal cancer protocols, especially given distinct molecular profiles including GNAS mutations and lower APC/TP53 alteration rates [45,46,47]. Here, GNAS is linked to colorectal cancer.